Clinical trial
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe…
NCT00134134 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00134134 |
|---|---|
| Title | Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa |
| Official title | An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hidradenitis Suppurativa |
| Intervention type | Drug |
| Interventions | efalizumab |
| Enrollment | 5 |
| Start date | Feb 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Aug 24, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: